Artículo

Identification and characterization of human interferon alpha inhibitors through a WISH cell line-based reporter gene assay

Bürgi Fissolo, María de Los Milagros Icon; Hernández, Paola ; Cabrera, Mauricio ; Cerecetto, Hugo ; González, Mercedes ; Kratje, Ricardo Bertoldo Icon; Raimondi, Alejandro Néstor ; Oggero Eberhardt, Marcos Rafael Icon; Bollati Fogolín, Mariela

Otros responsables

Fecha

10/2019

Editorial

Academic Press Inc Elsevier Science

Revista

Bioorganic Chemistry

Título del libro

Nombre del evento

Fecha del evento

Institución organizadora

ISSN

0045-2068

eISSN

ISBN

Idioma

Inglés

Tipo del evento

Resumen

Interferons (IFNs) are important glycoproteins which can stimulate or inhibit up to three hundred different genes encoding proteins involved in antiviral defense mechanisms, inflammation, adaptive immunity, angiogenesis and among other processes. Nevertheless, different genetic alterations may lead to interferon alpha (IFN-α) overproduction in human autoimmune diseases like systemic lupus erythematosus. As a consequence, IFN-α is a central molecule whose activity must be regulated to block their harmful effect on those disorders where the endogenous cytokine production constitutes the etiology of the illnesses. In this work, we evaluate the biological activity of eighty-eight compounds, from our own chemo-library, to find potential IFN-α inhibitors by using a reporter gene assay (RGA) WISH-Mx2/EGFP. We identified some compounds able to modulate negatively the IFN-α activity. The most active IFN-α inhibitors were further studied achieving promising results. In addition, some combinations of the most active compounds were analyzed accomplishing a stronger effect to decrease the IFN-α activity than each compound alone. Furthermore, the complete inhibition of the cytokine activity was reached with some combinations of compounds.

Aprobación

Revisión

Complementado por

Referenciado por

Licencia Creative Commons

Excepto donde se indique lo contrario, la licencia de este ítem se describe como by-nc-sa